Search
Miglustat
go.drugbank.com/drugs/DB00419ApprovedInvestigationalMiglustat was first developed as an anti-HIV agent in the 1990s. … It has recently been approved for treatment of progressive neurological symptoms in adult and pediatric patients in the European Union, Brazil, and South Korea.
Ripretinib
go.drugbank.com/drugs/DB14840ApprovedInvestigationalRipretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020. … Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]
Amivantamab
go.drugbank.com/drugs/DB16695ApprovedInvestigationalnon-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based … [A235103,A235118] Amivantamab was found to be more effective than the EGFR inhibitor [erlotinib] or the MET inhibitor [crizotinib] _in vivo_.
Oxcarbazepine
go.drugbank.com/drugs/DB00776ApprovedInvestigational- a pro-drug of the more active (S)-enantiomer is also marketed as a separate anti-epileptic under the name [eslicarbazepine]. … Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.
Products: NITRIS 300MG, TRILEPTAL 300MGLasofoxifene
go.drugbank.com/drugs/DB06202ApprovedInvestigationalWithdrawnIt was initially developed as Oporia by Pfizer as a treatment for postmenopausal osteoporosis and vaginal atrophy, in which were both rejected for approval by FDA. … Later Fablyn was developed as a result of a research collaboration between Pfizer and Ligand Pharmaceuticals with a newly submitted New Drug Application in 2008.
Dihydrocodeine
go.drugbank.com/drugs/DB01551ApprovedIllicitIt was marketed in 1911. … It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis
Defibrotide
go.drugbank.com/drugs/DB04932ApprovedInvestigationalIn the USA it is was approved in March, 2016 as Defitelio. … It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects).
Histrelin
go.drugbank.com/drugs/DB06788ApprovedInvestigationalWithdrawnHistrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. … [L41715] Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021.
Eugenol
go.drugbank.com/drugs/DB09086ApprovedInvestigationalEugenol is a naturally occurring phenolic molecule found in several plants such as cinnamon, clove, and bay leaves. … It has been used as a topical antiseptic as a counter-irritant and in dental preparations with zinc oxide for root canal sealing and pain control.
Busulfan
go.drugbank.com/drugs/DB01008ApprovedInvestigationalAccording to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen. … It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about.
Synonyms: 1, 4-Bis[methanesulfonoxy]butane, 1,4-Bis(methanesulfonoxy)butane